Synaptrix offers NOVABLOC, a drug-free solution for managing postoperative pain through targeted nerve block technology. This approach reduces reliance on opioids, minimizing the risk of addiction and enhancing patient recovery experiences.
Funding
$10.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Postoperative pain management often relies heavily on opioids, leading to potential risks of addiction, side effects, and prolonged recovery times for patients. Traditional pain management methods may not provide targeted relief, resulting in inadequate pain control and increased patient discomfort.
Solution
Synaptrix offers NOVABLOC, a non-pharmacological solution for postoperative pain management that utilizes targeted nerve block technology. This approach aims to reduce or eliminate the need for opioid-based pain relief, thereby minimizing the risk of addiction and associated side effects. By precisely targeting the nerves responsible for transmitting pain signals, NOVABLOC provides localized and effective pain control, potentially leading to improved patient recovery experiences and reduced reliance on systemic analgesics. The technology offers a drug-free alternative for managing pain following surgical procedures.
Target Audience
The primary target audience includes surgeons, anesthesiologists, and hospitals seeking to improve postoperative pain management protocols and reduce opioid consumption in patients.
Features
- Targeted nerve block technology for localized pain relief
- Non-pharmacological approach to minimize opioid reliance
- Potential for reduced side effects compared to opioid-based pain management
- Designed to enhance patient recovery experiences